Therapeutic Activity of DCC-2036, a Novel Tyrosine Kinase Inhibitor, Against Triple-Negative Breast Cancer Patient-Derived Xenografts by Targeting AXL/MET

International Journal of Cancer - United States
doi 10.1002/ijc.31915
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Identification of Novel Therapeutic Targets for Triple-Negative Breast Cancer

2012English

Development of a Vaccine Targeting Triple-Negative Breast Cancer

2013English

Targeting C-Met Receptor Tyrosine Kinase by the DNA Aptamer SL1 as a Potential Novel Therapeutic Option for Myeloma

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2018English

Targeting Tumour Microenvironment by Tyrosine Kinase Inhibitor

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2018English

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence After Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

Targeting MYC for Triple-Negative Breast Cancer Treatment

Oncoscience
Cancer ResearchOncology
2018English

Therapeutic Landscape in Mutational Triple Negative Breast Cancer

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2018English

Activity of BET-proteolysis Targeting Chimeric (PROTAC) Compounds in Triple Negative Breast Cancer

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

Pan-Tam Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-Pd-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer

Cancer Research
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy